David Foehr Sells 569 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) VP David Foehr sold 569 shares of the business’s stock in a transaction dated Monday, February 23rd. The shares were sold at an average price of $19.79, for a total transaction of $11,260.51. Following the sale, the vice president directly owned 18,331 shares of the company’s stock, valued at approximately $362,770.49. This represents a 3.01% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

David Foehr also recently made the following trade(s):

• On Tuesday, February 24th, David Foehr sold 781 shares of CeriBell stock. The stock was sold at an average price of $19.98, for a total transaction of $15,604.38.
• On Tuesday, February 3rd, David Foehr sold 5,556 shares of CeriBell stock. The shares were sold at an average price of $20.00, for a total value of $111,120.00.
• On Monday, January 5th, David Foehr sold 5,556 shares of CeriBell stock. The stock was sold at an average price of $22.60, for a total value of $125,565.60.
• On Wednesday, December 3rd, David Foehr sold 5,265 shares of CeriBell stock. The stock was sold at an average price of $16.83, for a total value of $88,609.95.

CeriBell Stock Performance

NASDAQ:CBLL traded down $0.95 during midday trading on Wednesday, reaching $18.95. 713,550 shares of the company traded hands, compared to its average volume of 351,326. The firm has a market capitalization of $703.05 million, a price-to-earnings ratio of -12.55 and a beta of 1.03. The company has a fifty day moving average price of $21.26 and a 200 day moving average price of $16.17. The company has a debt-to-equity ratio of 0.12, a current ratio of 12.65 and a quick ratio of 12.25. CeriBell, Inc. has a twelve month low of $10.01 and a twelve month high of $25.98.

CeriBell (NASDAQ:CBLL) last posted its earnings results on Tuesday, February 24th. The company reported ($0.36) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.43) by $0.07. CeriBell had a negative return on equity of 29.63% and a negative net margin of 63.35%.The company had revenue of $24.78 million for the quarter, compared to analysts’ expectations of $23.95 million. On average, analysts expect that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.

Analyst Ratings Changes

CBLL has been the subject of several recent analyst reports. JPMorgan Chase & Co. decreased their target price on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. BTIG Research reiterated a “buy” rating and set a $30.00 price objective on shares of CeriBell in a research report on Wednesday, January 28th. Canaccord Genuity Group raised their target price on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, December 17th. Finally, TD Cowen reaffirmed a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $24.67.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Squarepoint Ops LLC acquired a new position in shares of CeriBell during the second quarter valued at approximately $1,054,000. Geode Capital Management LLC boosted its stake in CeriBell by 55.4% during the 2nd quarter. Geode Capital Management LLC now owns 447,936 shares of the company’s stock valued at $8,391,000 after purchasing an additional 159,698 shares in the last quarter. Emerald Mutual Fund Advisers Trust increased its position in shares of CeriBell by 58.2% during the 3rd quarter. Emerald Mutual Fund Advisers Trust now owns 155,360 shares of the company’s stock valued at $1,785,000 after purchasing an additional 57,175 shares during the period. Police & Firemen s Retirement System of New Jersey raised its stake in shares of CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock worth $106,000 after buying an additional 3,502 shares in the last quarter. Finally, F m Investments LLC bought a new position in CeriBell during the second quarter valued at about $381,000.

CeriBell News Roundup

Here are the key news stories impacting CeriBell this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — CeriBell reported a loss of ($0.36) vs. consensus ($0.43) and revenue of $24.78M vs. $23.95M expectations, showing top‑line strength and a smaller-than-expected loss. Zacks: Q4 results
• Positive Sentiment: Management highlighted market expansion and revenue acceleration on the earnings call, which supports ongoing growth expectations for newborn hearing-screening adoption. Earnings call transcript
• Neutral Sentiment: FY2026 revenue guidance of $111.0M–$115.0M was issued, roughly in line with the Street estimate (~$112.7M) — guidance supports growth but isn’t a clear upside surprise. (Press release/earnings coverage.)
• Neutral Sentiment: Balance-sheet strength: very high current and quick ratios indicate ample liquidity, reducing short-term financing risk. (See filings/coverage.)
• Negative Sentiment: Insider selling: Director Josef Parvizi sold 16,714 shares (recently continued a pattern of sales), which can be viewed negatively by some investors. Insider selling report
• Negative Sentiment: Company remains unprofitable with a negative net margin (~‑63%), negative ROE, and an expected full‑year EPS loss — profitability timeline remains a key risk for valuation. Business Insider: results summary
• Negative Sentiment: Mixed analyst moves — at least one price-target cut alongside continued buy ratings elsewhere creates divergent expectations that can increase volatility. (Analyst coverage summarized in public filings/press coverage.)

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.